Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.
Location: Canada, Alberta, Edmonton
Employees: 11-50
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Althea Gro... | altheagrou... |
| - | Catalio Ca... | cataliocap... |
Mentions in press and media 8
| Date | Title | Description |
| 23.05.2025 | The Genetic Medicine Revolution: New Players and Innovations on the Horizon | The landscape of genetic medicine is shifting. New players are emerging, armed with innovative technologies and substantial funding. Stylus Medicine and Entos Pharmaceuticals are at the forefront of this revolution, each tackling unique cha... |
| 22.05.2025 | CureDuchenne Ventures Invests in Entos Pharmaceuticals | Entos Pharmaceuticals, an Edmonton, Canada-based biotech company that develops genetic medicines, received an investment from CureDuchenne Ventures. The amount of the deal was not disclosed. The company intends to use the funds to create a ... |
| 04.04.2025 | The Tug of War in Alzheimer’s Treatment: Kisunla’s Setback and the Rise of Innovative RNA Technologies | In the ever-evolving landscape of medical science, the battle against Alzheimer’s disease is a high-stakes game. Eli Lilly & Co. recently faced a significant setback with its Alzheimer’s drug, Kisunla. The European Medicines Agency (EMA... |
| 03.04.2025 | Entos Pharmaceuticals and Circio initiate collaboration to test novel platform for circVec circular RNA delivery | Entos Pharmaceuticals and Circio initiate collaboration to test novel platform for circVec circular RNA delivery Thu, Apr 03, 2025 07:00 CET Report this content Circio´s durable circVec DNA vectors will be combined with the Entos Fusogenix ... |
| 13.02.2025 | Entos Pharmaceuticals Awarded $4 Million From The California Institute For Regenerative Medicine | Entos Pharmaceuticals, a clinical-stage genetic medicines company committed to using its Fusogenix PLV technology to develop cures and improve the lives of patients and their families, announced that the California Institute for Regenerativ... |
| 29.07.2024 | Oisín Biotechnologies: $15 Million Raised To Mitigate Effects Of Age-Related Diseases | Oisín Biotechnologies (a privately held biotechnology company focused on mitigating the effects of age-related diseases) announced the first closing in a $15 million Series A funding round. AbbVie Ventures led the first close. And in connec... |
| 06.01.2022 | Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications | INDIANAPOLIS and EDMONTON, AB, Jan. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic ... |
| - | Entos Pharmaceuticals | “Entos Pharmaceuticals” |